StockNews.com Lowers Immunic (NASDAQ:IMUX) to Sell

StockNews.com lowered shares of Immunic (NASDAQ:IMUXFree Report) from a hold rating to a sell rating in a report published on Friday.

Immunic Price Performance

IMUX stock opened at $1.36 on Friday. The company has a fifty day moving average price of $1.30 and a 200 day moving average price of $1.28. Immunic has a 12 month low of $0.95 and a 12 month high of $3.11. The company has a market cap of $122.30 million, a price-to-earnings ratio of -0.64 and a beta of 2.07.

Immunic (NASDAQ:IMUXGet Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.03. As a group, analysts anticipate that Immunic will post -1 earnings per share for the current year.

Hedge Funds Weigh In On Immunic

A number of large investors have recently bought and sold shares of IMUX. LPL Financial LLC purchased a new position in Immunic during the 2nd quarter worth $28,000. American Century Companies Inc. purchased a new position in Immunic during the 3rd quarter worth $31,000. JPMorgan Chase & Co. raised its position in Immunic by 1,143.9% during the 4th quarter. JPMorgan Chase & Co. now owns 24,903 shares of the company’s stock worth $35,000 after buying an additional 22,901 shares during the last quarter. Two Sigma Securities LLC purchased a new position in Immunic during the 2nd quarter worth $36,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Immunic during the 1st quarter worth $37,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

(Get Free Report)

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Featured Stories

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.